Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Completed 19Unknown 8Withdrawn 4Active not recruiting 3Recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

NET 3Endocrine 3CNS 2Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × Interventional × 3-Iodobenzylguanidine × Clear all
NCT04614766 2024-04-29

SPORE-3

University of Iowa

Phase 1/2 Withdrawn
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT04831567 2022-05-19

MIBNET

AC Camargo Cancer Center

Phase 2 Withdrawn
EndocrineNET

Neuroendocrine Tumors

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Withdrawn
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡